| First penicillin-binding protein occupancy patterns of β-lactams and β-lactamase inhibitors in Klebsiella pneumoniae DS Sutaria, B Moya, KB Green, TH Kim, X Tao, Y Jiao, A Louie, ... Antimicrobial agents and chemotherapy 62 (6), 10.1128/aac. 00282-18, 2018 | 75 | 2018 |
| Comparable efficacy and better safety of double β-lactam combination therapy versus β‑lactam plus aminoglycoside in gram-negative bacteria in randomized, controlled trials Y Jiao, B Moya, MJ Chen, AP Zavascki, H Tsai, X Tao, DS Sutaria, ... Antimicrobial Agents and Chemotherapy 63 (7), 10.1128/aac. 00425-19, 2019 | 30 | 2019 |
| Fabrication of an EGF modified nanodiamonds-based anti-cancer drug targeted delivery system and drug carrier uptake visualization by 3D Raman microscopy X Chen, D Li, H Wang, Y Jiao, H Wang, Y Yu, J Zhi RSC advances 6 (50), 44543-44551, 2016 | 23 | 2016 |
| Novel cassette assay to quantify the outer membrane permeability of five β-lactams simultaneously in carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae TH Kim, X Tao, B Moya, Y Jiao, KB Basso, J Zhou, Y Lang, DS Sutaria, ... MBio 11 (1), 10.1128/mbio. 03189-19, 2020 | 18 | 2020 |
| Can pharmacokinetic studies assess the pulmonary fate of dry powder inhaler formulations of fluticasone propionate? G Hochhaus, MJ Chen, A Kurumaddali, U Schilling, Y Jiao, SK Drescher, ... The AAPS journal 23, 1-14, 2021 | 17 | 2021 |
| First penicillin-binding protein occupancy patterns for 15 β-lactams and β-lactamase inhibitors in Mycobacterium abscessus ARM Sayed, NR Shah, KB Basso, M Kamat, Y Jiao, B Moya, DS Sutaria, ... Antimicrobial agents and chemotherapy 65 (1), 10.1128/aac. 01956-20, 2020 | 17 | 2020 |
| A novel approach to improve the pharmacokinetic properties of 8-chloro-adenosine by the dual combination of lipophilic derivatisation and liposome formulation Y Jiao, X Wang, W Lu, Z Yang, Q Zhang European Journal of Pharmaceutical Sciences 48 (1-2), 249-258, 2013 | 16 | 2013 |
| Four decades of β-lactam antibiotic pharmacokinetics in cystic fibrosis JB Bulitta, Y Jiao, SK Drescher, A Oliver, A Louie, B Moya, X Tao, ... Clinical Pharmacokinetics 58, 143-156, 2019 | 15 | 2019 |
| Combating multidrug‐resistant bacteria by integrating a novel target site penetration and receptor binding assay platform into translational modeling Y Lang, NR Shah, X Tao, SM Reeve, J Zhou, B Moya, ARM Sayed, ... Clinical Pharmacology & Therapeutics 109 (4), 1000-1020, 2021 | 12 | 2021 |
| Novel population pharmacokinetic approach to explain the differences between cystic fibrosis patients and healthy volunteers via protein binding NR Shah, JB Bulitta, M Kinzig, CB Landersdorfer, Y Jiao, DS Sutaria, ... Pharmaceutics 11 (6), 286, 2019 | 10 | 2019 |
| Novel cassette assay to quantify the outer membrane permeability of five beta-lactams simultaneously in carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae … TH Kim, X Tao, B Moya, Y Jiao, KB Basso, J Zhou, Y Lang, DS Sutaria, ... | 8 | 2020 |
| First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers Y Jiao, TH Kim, X Tao, M Kinzig, CB Landersdorfer, SK Drescher, ... European Journal of Pharmaceutical Sciences 123, 416-428, 2018 | 8 | 2018 |
| Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling JB Bulitta, SH Paik, YH Chi, TH Kim, S Shin, CB Landersdorfer, Y Jiao, ... European Journal of Pharmaceutical Sciences 107, 32-44, 2017 | 7 | 2017 |
| Unraveling the pulmonary fate of fluticasone and friends: meeting the physiologic and pharmacokinetic challenges G Hochhaus, M Chen, J Shur, A Kurumaddali, U Schilling, Y Jiao, ... Respir Drug Deliv 2020, 139-146, 2020 | 5 | 2020 |
| Comparable bioavailability and disposition of pefloxacin in patients with cystic fibrosis and healthy volunteers assessed via population pharmacokinetics JB Bulitta, Y Jiao, CB Landersdorfer, DS Sutaria, X Tao, E Shin, R Höhl, ... Pharmaceutics 11 (7), 323, 2019 | 4 | 2019 |
| 肿瘤药物基因组学的研究进展 刘敬弢， 焦园园， 张艳华 国际药学研究杂志 41 (1), 51-56, 2014 | 4 | 2014 |
| 肿瘤分子靶向药物的临床研究及疗效评价 焦园园， 张艳华 中国医院用药评价与分析, 190-192, 2013 | 4 | 2013 |
| 2010~ 2011 年北京大学肿瘤医院 443 例药物不良反应报告分析 方向红， 宁华， 焦园园， 张艳华， 丁曦 山东医药 52 (34), 82-84, 2012 | 4 | 2012 |
| 全国 9 家肿瘤专科医院 2010 年抗肿瘤药利用分析 刘红， 宁华， 巩红， 焦园园， 张艳华 中国药房 22 (46), 4343-4346, 2011 | 4 | 2011 |
| 抗肿瘤药物相关用药错误的文献分析 范丽萍， 焦园园， 王睿晴， 张艳华 中国药房 29 (18), 2556-2560, 2018 | 3 | 2018 |
